But subsequent deterioration in insulin resistance and β-cell function similar to placebo
FRIDAY, July 8 (HealthDay News) -- Low-dose metformin/rosiglitazone therapy is associated with an initial delay in development of type 2 diabetes in individuals with impaired glucose tolerance, but it did not affect the worsening insulin resistance and β-cell dysfunction that occurs over time, according to a study published in the July issue of Diabetes Care.
Ravi Retnakaran, M.D., from Mount Sinai Hospital in Toronto, and colleagues evaluated the temporal changes in glycemic control, insulin sensitivity, and β-cell function in 207 participants from the Canadian Normoglycemia Outcome Evaluation trial. Participants from the rosiglitazone/metformin and placebo groups underwent annual oral glucose tolerance testing. The insulin sensitivity and β-cell function were assessed by the Matsuda index and the insulin secretion-sensitivity index-2, respectively.
The researchers found that glycemic parameters and insulin sensitivity showed improvement in patients in the rosiglitazone/metformin group in year one, but they subsequently deteriorated, similar to the placebo group. Generalized estimating equation analysis further indicated that both insulin sensitivity and β-cell function decreased significantly over time and showed no significant time-by-treatment interaction.
"These data suggest that low-dose rosiglitazone/metformin therapy had an early effect that decreased the subsequent development of diabetes during the trial but did not modify the natural history of worsening insulin resistance and β-cell dysfunction over time," the authors write.
Two authors disclosed financial ties to GlaxoSmithKline, which provided the study medication and funded the trial.
Abstract
Full Text (subscription or payment may be required)